AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9183321 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat starch-containing product
Number of subjects: 17
Study 9183321 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with celiac disease who tolerated wheat starch)
Number of subjects: 17
Study 1359096 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% tropicamide micro drops
Number of subjects: 20
Study 1359096 — intervention group
Group type: COMPARATOR
Intervention: Standard size drops (1% tropicamide and 10% phenylephrine)
Number of subjects: 20
Study 3887974 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Number of subjects: 10
Study 31130959 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticosteroids and/or adjuvant immunosuppressive drugs
Number of subjects: 0
Study 31130959 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel treatment targets
Number of subjects: 0
Study 29781648 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided ICBT via smartphone app
Number of subjects: 150
Study 29781648 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided ICBT via PC
Number of subjects: 150
Study 29781648 — intervention group
Group type: COMPARATOR
Intervention: Wait list control (WL)
Number of subjects: 150
Study 27459535 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 60
Study 27459535 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 60
Study 27459535 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 60
Study 24625392 — intervention group
Group type: EXPERIMENTAL
Intervention: α-synuclein levels in cerebrospinal fluid
Number of subjects: 300
Study 23867622 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 2-hour cold exposure at 17°C for 6 weeks
Number of subjects: 0
Study 23867622 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily ingestion of capsinoids for 6 weeks
Number of subjects: 0
Study 20106601 — intervention group
Group type: EXPERIMENTAL
Intervention: Unobserved induction
Number of subjects: 20
Study 20106601 — intervention group
Group type: COMPARATOR
Intervention: Observed induction
Number of subjects: 20
Study 18382005 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-mentoring behavioral intervention
Number of subjects: 418
Study 18382005 — intervention group
Group type: COMPARATOR
Intervention: Control group (time-equivalent attention-control)
Number of subjects: 418
Study 16361874 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Strategic Family Therapy (BSFT) for 3 months
Number of subjects: 40
Study 16361874 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 40
Study 12790259 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer education
Number of subjects: 222
Study 12790259 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional expression
Number of subjects: 222
Study 12790259 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 222
Study 10756964 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-free lithium hydroxide
Number of subjects: 16
Study 10756964 — intervention group
Group type: COMPARATOR
Intervention: Moist Drägersorb 800
Number of subjects: 16
Study 8968170 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (60 mg orally 2 h before induction and an infusion of 0.1 mg.kg‐1.h‐1 for 23 h)
Number of subjects: 30
Study 1477874 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether (n = 24), 9.6 mg/kg body weight intramuscularly over five days
Number of subjects: 47
Study 1477874 — intervention group
Group type: COMPARATOR
Intervention: chloroquine (n = 23), 25 mg/kg body weight orally
Number of subjects: 47
Study 1477874 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether
Number of subjects: 47
Study 1477874 — intervention group
Group type: COMPARATOR
Intervention: chloroquine
Number of subjects: 47
Study 3511402 — intervention group
Group type: EXPERIMENTAL
Intervention: Progabide (32 mg/kg mean daily dose, range 16 to 63)
Number of subjects: 19
Study 3511402 — intervention group
Group type: EXPERIMENTAL
Intervention: Progabide
Number of subjects: 19
Study 3511402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31900018 — intervention group
Group type: EXPERIMENTAL
Intervention: Value reference points
Number of subjects: 321
Study 31900018 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk preference
Number of subjects: 321
Study 31900018 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of hypertension, expectation, health literacy, opportunity costs
Number of subjects: 321
Study 31900018 — intervention group
Group type: EXPERIMENTAL
Intervention: Certainty effect, overconfidence, optimism
Number of subjects: 321
Study 31900018 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education and better health service resources
Number of subjects: 321
Study 30205906 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil–ketamine
Number of subjects: 70
Study 30205906 — intervention group
Group type: COMPARATOR
Intervention: Propofol–ketamine
Number of subjects: 70
Study 27294271 — intervention group
Group type: EXPERIMENTAL
Intervention: AERLI educational intervention (face-to-face educational session)
Number of subjects: 271
Study 27294271 — intervention group
Group type: COMPARATOR
Intervention: Standard harm reduction centers (without intervention)
Number of subjects: 271
Study 23799806 — intervention group
Group type: EXPERIMENTAL
Intervention: EPPM-based training curriculum
Number of subjects: 71
Study 23799806 — intervention group
Group type: COMPARATOR
Intervention: Control group (randomly assigned)
Number of subjects: 71
Study 22082089 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMETA Protocol (flumazenil 2 mg infusions on days 1, 2, 3, 22, 23; gabapentin 1200 mg to day 40; hydroxazine 50 mg to day 10)
Number of subjects: 120
Study 22082089 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication (with active hydroxazine only)
Number of subjects: 120
Study 20123357 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of molecular biomarkers in surgical UCB specimens
Number of subjects: 0
Study 20123357 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular biomarkers
Number of subjects: 0
Study 18721246 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Number of subjects: 2998
Study 18721246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2998
Study 15872350 — intervention group
Group type: EXPERIMENTAL
Intervention: CWU+PET (n = 51)
Number of subjects: 102
Study 15872350 — intervention group
Group type: COMPARATOR
Intervention: CWU (n = 51)
Number of subjects: 102
Study 15872350 — intervention group
Group type: EXPERIMENTAL
Intervention: PET
Number of subjects: 102
Study 15872350 — intervention group
Group type: COMPARATOR
Intervention: CT/MRI
Number of subjects: 102
Study 15872350 — intervention group
Group type: EXPERIMENTAL
Intervention: CWU+PET
Number of subjects: 102
Study 12664022 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine (10 mg, once daily)
Number of subjects: 28
Study 12664022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 10630824 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime administered as an intravenous bolus or as a rapid infusion
Number of subjects: 16
Study 8657838 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine
Number of subjects: 0
Study 8657838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2355106 — intervention group
Group type: EXPERIMENTAL
Intervention: HP 029 at 450 mg/day (150 mg three times a day)
Number of subjects: 24
Study 2355106 — intervention group
Group type: EXPERIMENTAL
Intervention: HP 029 at 300 mg/day (100 mg three times a day)
Number of subjects: 24
Study 2355106 — intervention group
Group type: EXPERIMENTAL
Intervention: HP 029 at 225 mg/day (75 mg three times a day)
Number of subjects: 24
Study 2355106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 322539 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine with pethidine
Number of subjects: 0
Study 322539 — intervention group
Group type: COMPARATOR
Intervention: Pethidine alone
Number of subjects: 0
Study 322539 — intervention group
Group type: COMPARATOR
Intervention: Pethidine at two dose levels
Number of subjects: 0
Study 322539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30376130 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-122 (60 mg EOW to 240 mg every week)
Number of subjects: 461
Study 30376130 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg EOW)
Number of subjects: 461
Study 30376130 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for PsA patients only)
Number of subjects: 461
Study 28372678 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal catheter (NPC)
Number of subjects: 60
Study 28372678 — intervention group
Group type: COMPARATOR
Intervention: Nasal cannula (NC)
Number of subjects: 60
Study 26318734 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral templates used by GPs in the intervention group.
Number of subjects: 500
Study 26318734 — intervention group
Group type: COMPARATOR
Intervention: Control group (no referral templates used).
Number of subjects: 500
Study 23764202 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist withdrawal
Number of subjects: 0
Study 23764202 — intervention group
Group type: COMPARATOR
Intervention: Control (non-withdrawal of GnRH agonist)
Number of subjects: 0
Study 22182483 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning Tool (PT)
Number of subjects: 858
Study 22182483 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Planning Tool and Text Reminders (PTT)
Number of subjects: 858
Study 22182483 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 858
Study 17895917 — intervention group
Group type: EXPERIMENTAL
Intervention: acute tryptophan depletion
Number of subjects: 16
Study 17895917 — intervention group
Group type: EXPERIMENTAL
Intervention: acute tyrosine/phenylalanine depletion
Number of subjects: 16
Study 17895917 — intervention group
Group type: EXPERIMENTAL
Intervention: acute tyrosine/phenylalanine/tryptophan depletion (combined monoamine depletion)
Number of subjects: 16
Study 17895917 — intervention group
Group type: COMPARATOR
Intervention: balanced/placebo control
Number of subjects: 16
Study 17146416 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 75-300 mg/day
Number of subjects: 1100
Study 17146416 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 20-60 mg/day
Number of subjects: 1100
Study 17146416 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER
Number of subjects: 1100
Study 17146416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1100
Study 17146416 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 1100
Study 14633326 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined androgen blockade (CAB) with bicalutamide
Number of subjects: 0
Study 14633326 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine with cisplatin
Number of subjects: 0
Study 14633326 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan with fluorouracil (and leucovorin)
Number of subjects: 0
Study 14633326 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 0
Study 14633326 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 0
Study 14633326 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab added to standard chemotherapy in HER2 positive metastatic breast cancer
Number of subjects: 0
Study 11052243 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% nitrous oxide (N2O) in oxygen (O2)
Number of subjects: 45
Study 11052243 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thiopental followed by mask inhalation with 100% O2 and 1.13% halothane
Number of subjects: 45
Study 11052243 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thiopental followed by mask inhalation with 2.52% enflurane
Number of subjects: 45
Study 11052243 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thiopental followed by mask inhalation with 1.73% isoflurane
Number of subjects: 45
Study 11052243 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% N2O in oxygen and 0.44% halothane
Number of subjects: 45
Study 11052243 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% N2O in oxygen and 0.86% enflurane
Number of subjects: 45
Study 11052243 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% N2O in oxygen and 0.75% isoflurane
Number of subjects: 45
Study 11052243 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam and ketamine
Number of subjects: 45
Study 11052243 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam and alfentanil
Number of subjects: 45
Study 11052243 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 45
Study 9446042 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler method (TCD) for examining blood flow velocities of middle cerebral arteries (MCAs)
Number of subjects: 34
Study 9446042 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex-scan method for examining blood flow velocities of extracranial parts of internal carotid arteries (ICAs)
Number of subjects: 34
Study 8405644 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin/Metronidazole
Number of subjects: 40
Study 8405644 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline/Metronidazole
Number of subjects: 40
Study 3769402 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin injection (0.5 micrograms/kg and 4 micrograms/kg)
Number of subjects: 3
Study 3769402 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin injection after inhalation of 5% bupivacaine aerosol
Number of subjects: 3
Study 3769402 — intervention group
Group type: COMPARATOR
Intervention: Control solution (not specified)
Number of subjects: 3
Study 30352556 — intervention group
Group type: EXPERIMENTAL
Intervention: Free baseline HIV self-testing (HIVST)
Number of subjects: 0
Study 30352556 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular (every 3 months) free HIVST with testing reminders
Number of subjects: 0
Study 30352556 — intervention group
Group type: COMPARATOR
Intervention: No free baseline HIVST
Number of subjects: 0
Study 30352556 — intervention group
Group type: COMPARATOR
Intervention: No offer of regular (every 3 months) free HIVST
Number of subjects: 0
Study 26762986 — intervention group
Group type: COMPARATOR
Intervention: Conventional electrophysiotherapy (ultrasound, laser, and interferential current techniques)
Number of subjects: 60
Study 26762986 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided galvanic electrolysis technique (USGET)
Number of subjects: 60
Study 24599195 — intervention group
Group type: EXPERIMENTAL
Intervention: Open repair
Number of subjects: 196
Study 24599195 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic repair
Number of subjects: 196
Study 22607165 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasoning and Rehabilitation Mental Health program (R&R2 MHP)
Number of subjects: 121
Study 22607165 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control (treatment as usual)
Number of subjects: 121
Study 21036883 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy plus chemoradiotherapy
Number of subjects: 101
Study 21036883 — intervention group
Group type: COMPARATOR
Intervention: PF chemoradiotherapy alone
Number of subjects: 101
Study 18416793 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure and meridian massage (15 minutes per session, 3 times daily for 10 days)
Number of subjects: 40
Study 18416793 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 40
Study 18416793 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure and meridian massage
Number of subjects: 40
Study 15864233 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily
Number of subjects: 90
Study 15864233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 12621740 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 199
Study 12621740 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin
Number of subjects: 199
Study 10520799 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital presentation
Number of subjects: 0
Study 10520799 — intervention group
Group type: COMPARATOR
Intervention: Out-of-hospital presentation
Number of subjects: 0
Study 7497653 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty after failed high tibial osteotomy
Number of subjects: 60
Study 7497653 — intervention group
Group type: COMPARATOR
Intervention: Total knee arthroplasty after failed unicompartmental knee arthroplasty
Number of subjects: 60
Study 2349916 — intervention group
Group type: EXPERIMENTAL
Intervention: Oyster diet
Number of subjects: 18
Study 2349916 — intervention group
Group type: EXPERIMENTAL
Intervention: Clam diet
Number of subjects: 18
Study 2349916 — intervention group
Group type: EXPERIMENTAL
Intervention: Crab diet
Number of subjects: 18
Study 2349916 — intervention group
Group type: EXPERIMENTAL
Intervention: Mussel diet
Number of subjects: 18
Study 2349916 — intervention group
Group type: EXPERIMENTAL
Intervention: Squid diet
Number of subjects: 18
Study 2349916 — intervention group
Group type: EXPERIMENTAL
Intervention: Shrimp diet
Number of subjects: 18
Study 6452793 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine (100 mg b.i.d.)
Number of subjects: 55
Study 6452793 — intervention group
Group type: COMPARATOR
Intervention: Maprotiline (75 mg b.i.d.)
Number of subjects: 55
Study 31220980 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater acculturation
Number of subjects: 76
Study 31220980 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater psychological distress
Number of subjects: 76
Study 31220980 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater alcohol problems
Number of subjects: 76
Study 31220980 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use and psychological distress
Number of subjects: 76
Study 29578373 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) training, 40 hours
Number of subjects: 66
Study 29578373 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 66
Study 26647412 — intervention group
Group type: EXPERIMENTAL
Intervention: New Medicine Service (NMS)
Number of subjects: 504
Study 26647412 — intervention group
Group type: COMPARATOR
Intervention: Normal practice
Number of subjects: 504
Study 26647412 — intervention group
Group type: EXPERIMENTAL
Intervention: NMS
Number of subjects: 504
Study 24871247 — intervention group
Group type: EXPERIMENTAL
Intervention: Google
Number of subjects: 48
Study 24871247 — intervention group
Group type: COMPARATOR
Intervention: Summary Resource
Number of subjects: 48
Study 21574826 — intervention group
Group type: EXPERIMENTAL
Intervention: LESS cholecystectomy
Number of subjects: 60
Study 21574826 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 60
Study 20669296 — intervention group
Group type: EXPERIMENTAL
Intervention: Melevodopa/carbidopa effervescent tablets (M/C)
Number of subjects: 221
Study 20669296 — intervention group
Group type: COMPARATOR
Intervention: Standard oral formulation levodopa/carbidopa tablets (L/C)
Number of subjects: 221
Study 17326911 — intervention group
Group type: COMPARATOR
Intervention: Pavulon (group 1)
Number of subjects: 30
Study 17326911 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (group 3)
Number of subjects: 30
Study 17326911 — intervention group
Group type: EXPERIMENTAL
Intervention: Both midazolam and pavulon (group 2)
Number of subjects: 30
Study 16013016 — intervention group
Group type: COMPARATOR
Intervention: Standard bicarbonate dialysis (unselected filters)
Number of subjects: 51
Study 16013016 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocompatible treatments (on-line hemofiltration or HD with ultra-pure dialysate and biocompatible membranes)
Number of subjects: 51
Study 16013016 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocompatible treatments
Number of subjects: 51
Study 12408283 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulator containing Mycobacterium w
Number of subjects: 134
Study 12408283 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 134
Study 9624239 — intervention group
Group type: EXPERIMENTAL
Intervention: low‐dose short‐term chemotherapy (one cycle of doxorubicin, vincristin (AV) and one cycle of cyclophosphamide, methotrexate, fluorouracil (CMF))
Number of subjects: 277
Study 9624239 — intervention group
Group type: COMPARATOR
Intervention: no chemotherapy
Number of subjects: 277
Study 8091320 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventstream nebuliser
Number of subjects: 8
Study 8091320 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventstream nebuliser at 5.0 mg dose
Number of subjects: 8
Study 8091320 — intervention group
Group type: COMPARATOR
Intervention: Hudson nebuliser
Number of subjects: 8
Study 3415710 — intervention group
Group type: EXPERIMENTAL
Intervention: ISMN‐20 (elantan 20)
Number of subjects: 3624
Study 3415710 — intervention group
Group type: EXPERIMENTAL
Intervention: ISMN‐50 (elantan long)
Number of subjects: 3624
Study 30559838 — intervention group
Group type: EXPERIMENTAL
Intervention: PFOA group
Number of subjects: 51
Study 30559838 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 27546446 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (36 IU)
Number of subjects: 30
Study 27546446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 25022724 — intervention group
Group type: EXPERIMENTAL
Intervention: DSS module added to existing computer decision support system
Number of subjects: 360
Study 22406757 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g/kg of alcohol
Number of subjects: 0
Study 22406757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19558387 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory flow resistive loading (IFRL)
Number of subjects: 24
Study 19558387 — intervention group
Group type: COMPARATOR
Intervention: Sham-IFRL
Number of subjects: 24
Study 19558387 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24